Inside-Out Membrane Vesicles Explained

August 2026 · 8 min read

If you are new to DMPK transporter assays, the term “inside-out membrane vesicles” comes up immediately — and it is rarely explained from the ground up. What are they, exactly? How are they made? Why does the inside-out orientation matter? And why can’t you just use cells?

This guide answers all of it — without assuming prior membrane biology knowledge.

Start with the biology: what ABC transporters do in a normal cell

ATP-binding cassette (ABC) transporters are membrane proteins that use the energy of ATP hydrolysis to actively transport substrates across cell membranes — against a concentration gradient. In the context of drug pharmacokinetics, the most clinically relevant ABC transporters are efflux pumps: they move drugs raus of cells.

In a living cell, these transporters are embedded in the plasma membrane with a specific orientation:

This is why these transporters are called efflux pumps: P-glycoprotein (P-gp) in the intestinal wall pumps drugs back into the gut lumen, reducing oral bioavailability. BSEP in the hepatocyte canalicular membrane pumps bile salts into bile. BCRP at the blood-brain barrier pumps drugs out of the CNS.

The problem with studying efflux transporters in intact cells

To measure whether your drug candidate is a substrate or inhibitor of an ABC transporter, you need to be able to control what the transporter is exposed to and measure what it does. In an intact cell, this is technically difficult for three reasons:

  1. The drug must cross the membrane to reach the substrate-binding site. For a drug to interact with an efflux transporter in a living cell, it first has to enter the cell by passive diffusion. High-permeability compounds cross so fast that efflux pump activity is overwhelmed by passive diffusion — making the efflux pump appear inactive even when it is not.
  2. Multiple transporters are active simultaneously. Cells express many transporters at once, making it impossible to isolate the contribution of a single specific transporter without selective inhibitors — which are not available for all transporters (no selective inhibitor exists for BSEP or most MRPs).
  3. The substrate-binding site is inaccessible from outside the cell. Because the binding site faces the cytoplasm, you cannot directly expose your test compound to the transporter without cell uptake first occurring.

This is where inside-out vesicles solve the problem elegantly.

What “inside-out” means — the key concept

When membrane vesicles are prepared from cells overexpressing an ABC transporter, a proportion of the vesicles form with their membrane inverted — the side that was originally facing the cytoplasm now faces the outside of the vesicle. This is the “inside-out” orientation.

In an inside-out vesicle:

This means: while ABC transporters typically mediate the efflux of substrates from cells, transporters expressed on these inside-out vesicles import substrates into the vesicles. The direction of transport is reversed — but the biochemistry is identical to what happens in vivo.

The amount of substrate accumulated inside the vesicle after a defined incubation period, measured after rapid filtration to separate vesicles from the incubation buffer, is the direct readout of transporter activity.

How inside-out vesicles are made

The production process follows established membrane biochemistry protocols:

  1. Expression system selection
    Vesicles can be prepared from purified plasma membranes isolated from insect cells (e.g., Sf9 or Sf21) overexpressing ABC transporters, or by transfecting mammalian cells (e.g., HEK293, HeLa, V79 or MDCK). Sf9 insect cells infected with baculovirus carrying the transporter gene are the most widely used system — they express extremely high levels of the transporter protein, yielding vesicle preparations with robust transport activity and low background. HEK293-based vesicles are increasingly used for specific transporters (BCRP, MRP family) where mammalian post-translational modifications improve functional activity.
  2. Cell lysis and membrane isolation
    Cells are disrupted by nitrogen cavitation or homogenisation under controlled conditions. The crude membrane fraction is isolated by differential centrifugation — low-speed spins remove cell debris and nuclei; high-speed ultracentrifugation pellets the membrane fraction.
  3. Vesicle formation by nitrogen cavitation
    The membrane fraction is resuspended and subjected to nitrogen cavitation — pressurised nitrogen gas is dissolved into the membrane suspension, and rapid depressurisation causes the membranes to vesiculate (form closed spherical structures). After everting the vesicles by a special process, the substrate binding site that is originally expressed inside of the vesicles will be everted to the outside — creating the inside-out orientation that makes the assay work.
  4. Purification and characterisation
    The vesicle preparation is purified by sucrose gradient centrifugation to enrich the inside-out fraction. Transporter activity is validated using a known probe substrate (e.g. taurocholic acid for BSEP, estrone-3-sulfate for BCRP, vinblastine for P-gp) in the presence and absence of ATP. The ratio of ATP-dependent to AMP-dependent transport (the “assay window”) must meet minimum specifications before the preparation is released for use.
  5. Aliquoting and storage
    Commercial vesicles can be stored in aliquots at −80°C without loss of activity — repeated freeze/thaw cycles are not required — making them useful for characterising transporter interactions by eliminating the labour and variability involved in their preparation. A single preparation can provide hundreds of assay-ready aliquots with consistent activity across months of use.

How the vesicular transport assay works — step by step

Once you have inside-out vesicles, the assay protocol is straightforward:

  1. Thaw vesicles on ice (one freeze-thaw cycle per aliquot; do not refreeze)
  2. Prepare incubation mix: vesicles (typically 50 µg protein/well) + probe substrate at Km concentration + ATP regenerating system (ATP + creatine phosphate + creatine kinase) in assay buffer
  3. Add test compound at defined concentrations (inhibitor format) or add vehicle (substrate format)
  4. Incubate at 37°C for 5–30 minutes (transporter-specific)
  5. Stop reaction by rapid filtration through glass fibre filter plates (GF/B or similar) with ice-cold wash buffer — this separates vesicle-enclosed compound from free compound in the buffer
  6. Quantify substrate accumulated in vesicles by scintillation counting (radiolabelled substrate), LC-MS/MS, or fluorescence, depending on the probe substrate used
  7. Calculate ATP-dependent transport = signal in ATP wells − signal in AMP control wells (AMP cannot fuel transport, providing the non-specific background)

Für inhibition assays: the reduction in ATP-dependent substrate accumulation at each test compound concentration gives the IC50. This is the primary regulatory endpoint for DDI assessment.

Für Substrat-Assays: the test compound itself (with radiolabel or LC-MS detection) is measured for accumulation. ATP-dependent accumulation confirms substrate status.

Sf9 vs. HEK293 vesicles — which is better?

Both expression systems produce functional inside-out vesicles, but they have different characteristics that affect assay performance:

ParameterSf9 (insect cell)HEK293 (mammalian)
Expression levelVery high — baculovirus system gives massive overexpressionHigh — stable transfection, lower than Sf9 but sufficient
Lipid compositionInsect cell lipids — lower cholesterol than mammalianMammalian lipids — more physiologically relevant membrane environment
BCRP activityRequires cholesterol loading for full BCRP activityNative cholesterol content supports BCRP activity without modification
Post-translational modificationsPartial — insect cell glycosylation differs from humanHuman-like — more relevant for glycosylation-dependent activity
IC50 concordanceGood correlation with HEK293 for most transportersReference system for BCRP; preferred for some MRP family members
Cell4Pharma kitsSf9-based for P-gp, BSEPHEK293-based for MRP1–MRP8, BCRP

Why the control vesicle is essential

Every vesicular transport assay requires a control vesicle — prepared from the same cell line without the transporter gene (non-transfected parental cells). This control accounts for:

ATP-dependent transport by the specific transporter = (ATP signal in transporter vesicle) − (ATP signal in control vesicle). Omitting the control vesicle is a common error that inflates apparent transport activity and produces false-positive substrate results. SeamlessBio supplies the Cell4Pharma Control Vesicle Kit matched to the transporter vesicle preparations for accurate background subtraction.

Ready-to-use vs. in-house prepared vesicles

Historically, vesicle preparation was a specialised laboratory skill requiring ultracentrifuges, nitrogen cavitation equipment, and weeks of optimisation. Today, ready-to-use commercial vesicle kits eliminate this entirely.

Since commercial vesicles can be stored in aliquots at −80°C without loss of activity and repeated freeze/thaw cycles are not required, they are useful for characterising transporter interactions by eliminating the labour and variability involved in their preparation.

For in-house DMPK teams running IND-enabling transporter panels, ready-to-use kits provide same-day results, eliminated preparation variability, and validated QC data that can be referenced in regulatory submissions. The Cell4Pharma series distributed by SeamlessBio covers the complete panel of ABC transporters required for IND-enabling DMPK packages:

→ View the full Cell4Pharma portfolio at SeamlessBio

Key takeaways — the five-point summary

  1. Inside-out = substrate-binding site faces outward. This allows direct access of your test compound to the transporter without cell uptake — eliminating passive permeability as a confounding variable.
  2. ATP-dependent accumulation is the signal. The difference between ATP and AMP control wells is specific transporter activity. The AMP control accounts for non-specific trapping.
  3. Sf9 and HEK293 both work — different strengths. Sf9 for high expression; HEK293 for physiologically relevant membrane and BCRP activity without cholesterol supplementation.
  4. Always include the control vesicle. Non-transfected membrane background must be subtracted for accurate IC50 and substrate determination.
  5. Commercial kits give same-day results. No preparation required — thaw, run, measure. Validated QC data included for regulatory reference.

Further reading on seamlessbio.de:

Questions about vesicle kit selection, assay setup, or regulatory requirements? Contact us at info@seamlessbio.de oder request a quote.

Schreibe einen Kommentar

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind mit * markiert

Benötigen Sie eine Chargenreservierung oder ein Testmuster?

Reservieren Sie Ihre validierte FBS- oder Humanserum-Charge – ohne Vorauszahlung.
Kostenlose Testmuster auf Anfrage.

Name
+49 851 xxxx
Wie sind Sie auf uns aufmerksam geworden?